Filtered By:
Specialty: Neurology
Condition: Multiple Sclerosis

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 440 results found since Jan 2013.

Glatiramer acetate does not protect from acute ischemic stroke in mice
Conclusions Glatiramer acetate failed to protect from acute ischemic stroke in our hands. Further studies are needed to assess the true therapeutic potential of glatiramer acetate and related immunomodulators in brain ischemia.
Source: Experimental and Translational Stroke Medicine - February 27, 2014 Category: Neurology Source Type: research

Natalizumab Versus Placebo in Patients with Acute Ischemic Stroke (AIS): Results from ACTION, a Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase 2 Clinical Trial (S7.005)
CONCLUSIONS: A single dose of natalizumab administered up to 9 hours after stroke onset did not reduce focal infarct volume growth, but natalizumab appeared to be associated with important functional outcome improvements sustained over 90 days. Further natalizumab studies for AIS are warranted. Support: Biogen.Disclosure: Dr. Elkins holds stock and/or stock options in Biogen, which sponsored research in which Dr. Elkins was involved as a researcher. Dr. Elkind has received personal compensation in and editorial capacity for serving as an Associate Editor of the journal Neurology. Dr. Veltkamp has received research support ...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Elkins, J., Elkind, M., Veltkamp, R., Montaner, J., Johnston, S., Singhal, A., Becker, K., Lansberg, M., Chang, I., Tang, W., Gheuens, S., Mehta, L. Tags: Stroke Clinical Trials Source Type: research

Glatiramer acetate does not protect from acute ischemic stroke in mice
ConclusionsGlatiramer acetate failed to protect from acute ischemic stroke in our hands. Further studies are needed to assess the true therapeutic potential of glatiramer acetate and related immunomodulators in brain ischemia.
Source: Experimental and Translational Stroke Medicine - February 27, 2014 Category: Neurology Source Type: research

Dalfampridine Improves Sensorimotor Function in Rats With Chronic Deficits After Middle Cerebral Artery Occlusion Basic Sciences
Conclusions— Dalfampridine improves sensorimotor function in the rat permanent middle cerebral artery occlusion model. Dalfampridine extended-release tablets (prolonged release fampridine outside the United States) are used to improve walking in patients with multiple sclerosis, and these preclinical data provide a strong rationale for examining the potential of dalfampridine to treat chronic stable deficits in stroke patients. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01605825
Source: Stroke - June 24, 2013 Category: Neurology Authors: Iaci, J. F., Parry, T. J., Huang, Z., Finklestein, S. P., Ren, J., Barrile, D. K., Davenport, M. D., Wu, R., Blight, A. R., Caggiano, A. O. Tags: Animal models of human disease, Other Stroke Treatment - Medical Basic Sciences Source Type: research

Misdiagnosis in Young Patients with Ischemic Stroke (P7.122)
Conclusions It is essential to increase awareness that young patients with stroke may present to emergency department with minor symptoms of artery dissection mainly involving the posterior circulation and lacking cardiovascular risk factors.Disclosure: Dr. Leon has nothing to disclose. Dr. Pantiu has nothing to disclose. Dr. Quiroga has nothing to disclose. Dr. Bonardo has nothing to disclose. Dr. Uribe has nothing to disclose. Dr. Mazziotti has received research support from Shire Pharmaceuticals Group. Dr. Zinnerman has nothing to disclose. Dr. Martinez has nothing to disclose. Dr. Sotelo has nothing to disclose. Dr. Ju...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Leon, L., Pantiu, F., Quiroga, J., Bonardo, P., Uribe, C., Mazziotti, J., Zinnerman, A., Martinez, A., Sotelo, A., Jure, L., Nofal, P., Bendersky, E., Sposato, L. A., Riccio, P., Reisin, R., Fernandez Pardal, M. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke in Young Source Type: research

Stroke Subtypes and Risk Factors in Saudi Arabia (P1.124)
CONCLUSION: Non-cardioembolic disease was the overwhelming stroke mechanism in this middle-eastern cohort with only 4[percnt] of patients have cardioembolic stroke, in comparison to roughly 20[percnt] reported in Western cohorts. In part, these differences may be explained by deficient prolonged cardiac monitoring. However the high prevalence of atherothrombotic risk factors and overrepresentation of non-cardioembolic stroke suggests a need to optimize atherothrombotic stroke risk factor management within our populationDisclosure: Dr. Al Harbi has nothing to disclose. Dr. Shoamanesh has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Al Harbi, A., Shoamanesh, A. Tags: Cerebrovascular Disease: Epidemiology Source Type: research

Increased risk of ischaemic stroke among patients with multiple sclerosis
ConclusionsMultiple sclerosis is declared to be associated with an increased risk in developing stroke, which requires closer attention to this group of patients for stroke prevention, especially in the younger population.
Source: European Journal of Neurology - November 29, 2014 Category: Neurology Authors: C.‐H. Tseng, W.‐S. Huang, C.‐L. Lin, Y.‐J. Chang Tags: Original Article Source Type: research

Changing course of Multiple Sclerosis (MS) after stroke: Excessive disease activity in a MS patient after cerebral infarction (P1.122)
CONCLUSIONS: This is a rare case of MS exacerbation after stroke in a patient with long-standing MS. The clear temporal relation with an increase of MS disease activity after stroke suggests possible interactions. One explanation could be an opening of the blood brain barrier after stroke with influx of activated immune cells into the central nervous system and consecutive MS exacerbation.Disclosure: Dr. Poellmann has received personal compensation for activities with Pfizer Inc., Novartis, Biogen Idec, and Merck Serono. Dr. Starck has nothing to disclose. Dr. Kümpfel has received personal compensation for activities ...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Poellmann, W., Starck, M., Kuempfel, T., Koehler, J. Tags: MS and CNS Inflammatory Diseases: Symptoms, Specific Symptomatic Treatment, Co-morbidities, and Costs Source Type: research

Reserve, Resilience and Recovery in Stroke: A Meta-Narrative Review (P3.199)
Conclusion: There is an urgent need to individualize outcomes in stroke systematically by implementing well validated concepts from various related fields to improve patient centered decision-making in acute stroke care.Disclosure: Dr. Dangayach has nothing to disclose. Dr. Grewal has nothing to disclose. Dr. Gordon has nothing to disclose. Dr. Mayer has received research support from Non-Invasive Medical Systems, Inc. and General Electric.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Dangayach, N., Grewal, H., Gordon, E., Mayer, S. Tags: Neurocritical Care: Clinical Science Source Type: research

Inherited and Uncommon Causes of Stroke
This article is a practical guide to identifying uncommon causes of stroke and offers guidance for evaluation and management, even when large controlled trials are lacking in these rarer forms of stroke. Recent Findings: Fabry disease causes early-onset stroke, particularly of the vertebrobasilar system; enzyme replacement therapy should be considered in affected patients. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), often misdiagnosed as multiple sclerosis, causes migraines, early-onset lacunar strokes, and dementia. Moyamoya disease can cause either ischemic or he...
Source: CONTINUUM: Lifelong Learning in Neurology - February 1, 2017 Category: Neurology Tags: Review Articles Source Type: research

Characteristics of Code Stroke Cases in a Level 1 Trauma U.S. Military Treatment Facility: Comparison with a Civilian Stroke Center (P3.265)
Conclusions:The proportion of code strokes ultimately diagnosed with AISor TIA in our facility is lower than that reported in a civilian stroke center, and the proportion of functional diagnoses is higher. Further studies are needed to describe the reasons for these differences, which may be unique to military populations.Disclosure: Dr. Koehn has nothing to disclose. Dr. Williams has nothing to disclose. Dr. Chao has nothing to disclose. Dr. Frattalone has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Koehn, T., Williams, J., Chao, W., Frattalone, A. Tags: Cerebrovascular Disease Epidemiology Source Type: research

Multiple Sclerosis and Stroke (P6.169)
Conclusion: There are consistent differences between the rates of ischemic stroke and TIA in patients with MS compared to those without MS, possibly indicating common inflammatory mechanisms.Disclosure: Dr. Sung has nothing to disclose. Dr. Amezcua has received personal compensation for activities with Biogen Idec, Questcor, Novartis and Acorda Therapeutics. Dr. Amezcua has received research support from Novartis and Acorda Therapeutics. Dr. Cen has nothing to disclose. Dr. Krug has nothing to disclose. Dr. Sanossian has received personal compensation for activities with Boehringer-Ingelheim Pharmaceutical Inc.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Sung, E., Amezcua, L., Cen, S., Krug, A., Sanossian, N. Tags: Multiple Sclerosis Symptoms and Comorbidities Source Type: research

Natalizumab: a new therapy for acute ischemic stroke?
This article reviews the main experimental studies on the blockage of CD49d and identifies the potential underlying causes for their inconclusive results. Despite these divergences and the difficulties in translation of experimental studies, a phase II clinical trial has recently been conducted to evaluate the efficacy of Natalizumab in stroke patients (ACTION trial). Preliminary results of the trial are also discussed here, together with a general overview of the emerged importance of the neuroprotective strategies based on the mitigation of post-stroke neuroinflammation. Expert commentary: Despite Natalizumab showing pos...
Source: Expert Review of Neurotherapeutics - August 2, 2016 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Translation into Brazilian Portuguese, cross-cultural adaptation, reliability and validation of the Functional Ambulation Classification for the categorization of ambulation following a stroke in a clinical setting.
CONCLUSION: The translation, cross-cultural adaptation and measurement properties demonstrated that the FAC is a valid, reliable clinical measure for the categorization of ambulation in the Brazilian population of stroke survivors in a clinical setting. PMID: 32390129 [PubMed - in process]
Source: Revista de Neurologia - May 13, 2020 Category: Neurology Authors: Elord C, Corrêa FI, Pereira GS, Silva SM, Corrêa JC Tags: Rev Neurol Source Type: research

Neutralizing RGMa with Elezanumab Promotes Cerebroprotection and Recovery in Rabbit Middle Cerebral Artery Occlusion
AbstractRepulsive guidance molecule A (RGMa) is an inhibitor of neuronal growth and survival which is upregulated in the damaged central nervous system following acute spinal cord injury (SCI), traumatic brain injury, acute ischemic stroke (AIS), and other neuropathological conditions. Neutralization of RGMa is neuroprotective and promotes neuroplasticity in several preclinical models of neurodegeneration and injury including multiple sclerosis, AIS, and SCI. Given the limitations of current treatments for AIS due to narrow time windows to intervention (TTI), and restrictive patient selection criteria, there is significant...
Source: Translational Stroke Research - June 16, 2023 Category: Neurology Source Type: research